MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database

作者：Maria Lucia Reale, Francesco Passiglia, Federico Cappuzzo, Gabriele Minuti, Mario Occhipinti, Alessandra Bulotta, Angelo Delmonte, Claudio Sini, Domenico Galetta, Elisa Roca, Giacomo Pelizzari, Diego Cortinovis, Eleonora Gariazzo, Sara Pilotto, Fabrizio Citarella, Emilio Bria, Paola Muscolino, Daniele Pozzessere, A. Carta, Daniele Pignataro, L. Calvetti, F. Leone, Marco Banini, Concetta Di Micco, Enke Baldini, Adolfo Favaretto, Umberto Malapelle, Silvia Novello, Giulia Pasello, Marcello Tiseo · 发表于：ESMO Open · 年份：2024 · DOI：10.1016/j.esmoop.2024.103680 · 被引用次数：11 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Research Studies、Lung Cancer Diagnosis and Treatment

BACKGROUND: Mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare alteration in non-small-cell lung cancer (NSCLC), occurring in about 3%-4% of cases. Here we report disease and patient characteristics, and efficacy and tolerability of MET inhibitors among advanced METex14 NSCLC patients from the Italian real-world registry ATLAS. MATERIALS AND METHODS: Clinical-pathological and molecular data, and treatment efficacy/tolerability outcomes were retrospectively collected from the ATLAS registry. RESULTS: From July 2020 to July 2023 a total of 146 METex14 advanced NSCLC patients were included across 27 Italian centers. Median age was 74 years, and most patients were male (52%), with an Eastern Cooperative Oncology Group performance status < 2 (72%) and adenocarcinoma subtype (83%). One hundred and twenty-five out of 146 (86%) patients received at least one line of systemic anticancer therapy. Fifty-six (38%) were treated with capmatinib and 34 (23%) with tepotinib. 29% and 52% of them received targeted treatment in the first and second line, respectively. In the cohort of patients treated with MET inhibitors, the response rate (RR) was 37% (33% in previously treated patients and 46% in treatment-naïve) with a disease control rate of 62%. With a median follow-up of 10.8 months, progression-free survival was 6.6 months [95% confidence interval (CI) 4.3-8.3 months] and overall survival was 10.7 months (95% CI 7.2-19.3 months). In patients with measur...